

CURRICULUM VITAE COVER SHEET
Christopher M. Jones, PharmD, DrPH, MPH
April 2022

PERFORMANCE

- **Acting Director**, National Center for Injury Prevention and Control (NCIPC), CDC Jun 2021-present
- Acting Communications Director, Centers for Disease Control and Prevention Jan 2021-Apr 2021
- **Deputy Director**, National Center for Injury Prevention and Control (NCIPC), CDC May 2020-present
- Senior Advisor, and Associate Director, Office of Strategy and Innovation, NCIPC, CDC Sep 2018-May 2020
- Incident Manager and Deputy Incident Manager, 2019 CDC Lung Injury Emergency Response Sep 2019-Jan 2019
- Deputy Goal Leader, HHS Agency Priority Goal on Opioids Sep 2016-Present
- Co-Chair, HHS Opioids and Controlled Substances Interagency Committee Jun 2017-Jun 2021
- **Director, National Mental Health and Substance Use Policy Laboratory**, SAMHSA Jan 2018-Sep 2018
- **Acting Associate Deputy Assistant Secretary**, Science and Data Policy, ASPE, HHS Dec 2016-Dec 2017
- **Director, Division of Science Policy**, ASPE, HHS Sep 2015-Dec 2017
- Co-Chair, Federal Interagency Medicolegal Death Investigation Work Group Feb 2016-present
- Co-Chair, Administration's Combatting Antibiotic-Resistant Bacteria Task Force Sep 2016-Dec 2017
- HHS lead, National Security Council Transnational Organized Crime Interagency Policy Committee Mar 2016-Sep 2018
- **Authored >100 peer-reviewed papers on substance use, mental health, overdose, suicide, and other topics** 2005-present
- Keynote speaker or presenter on substance use, mental health, suicide, ACEs, at over 300 scientific meetings 2010-present
- **Detail to the Office of the Surgeon General** to lead development of the Turn the Tide Rx Campaign (6 months) 2015
- Detail to the Office of the Assistant Secretary for Health to lead development of Report to Congress on Drug Use (6 months) 2013
- **Detail to White House Office of National Drug Control Policy** as Senior Public Health Advisor (12 months) 2010-2011
- **Secretary's Distinguished Service Award (HHS)** 2015, 2016, 2018
- Outstanding Unit Citation (PHS) for Reversing the Mortality Rate in the Nation's Drug Overdose Crisis 2019
- **Outstanding Service Medal (PHS)** for dedication, professionalism, and exceptional public health leadership to further the President's National Drug Control Program 2012
- **Commendation Medal (PHS)** for leadership and advancement of the CDC's prescription drug overdose program 2015
- Commendation Medal (PHS) for Exceptional Public health leadership on prescription drug abuse 2015
- Commendation Medal (PHS) for professionalism, leadership & commitment to the FDA safety & risk communication team 2009
- **Outstanding Unit Citation (PHS)** for the immediate response in approving drugs, vaccines, diagnostics, and respiratory devices to protect the public from the influenza pandemic 2011
- **Exceptional Proficiency Promotion to O-5 and O-6** 2013, 2017

EDUCATION, TRAINING and PROFESSIONAL DEVELOPMENT

- **Doctor of Public Health**, Health Policy, George Washington University May 2019
- Office of Personnel Management, Federal Executive Institute, Leadership for a Democratic Society May 2015
- Master of Public Health, Health Policy and Management, New York Medical College May 2011
- **Doctor of Pharmacy**, Mercer University May 2006
- Bachelor of Science, Biology, Reinhardt College Dec 2004
- Top Secret/SCI Clearance Active

CAREER PROGRESSION and POTENTIAL

- Deputy Director, National Center for Injury Prevention and Control, CDC, Atlanta, GA May 2020-present
- Senior Advisor and Associate Director, Office of Strategy and Innovation, CDC, Atlanta, GA Sep 2018-May 2020
- Director, National Mental Health and Substance Use Policy Laboratory, SAMHSA, Rockville, MD Jan 2018-Sep 2018
- Acting Associate Deputy Assistant Secretary, ASPE/HHS, Washington, DC Dec 2016-Dec 2017
- Director, Division of Science Policy, ASPE/HHS, Washington, DC Sep 2015-Dec 2017
- Senior Advisor, Office of the Commissioner, FDA, Silver Spring, MD Feb 2014-Sep 2015
- Team Leader, CDC, Atlanta, GA Jul 2011-Feb 2014
- Senior Public Health Advisor, detail to Office of National Drug Control Policy, Washington, DC Aug 2010-Jul 2011
- Team Leader, FDA, Silver Spring, MD Mar 2010-Aug 2010
- Health Promotion Officer, Food and Drug Administration, Silver Spring, MD Mar 2009-Mar 2010

CURRICULUM VITAE

Christopher M. Jones, PharmD, DrPH, MPH

Captain, US Public Health Service

Acting Director

National Center for Injury Prevention and Control

U.S. Centers for Disease Control and Prevention

Atlanta, GA

O: 404-498-0756 | C: 770-367-6739 |

W: fjr0@cdc.gov | P: cjonespharmd@gmail.com

Education:

Doctor of Public Health, Health Policy

George Washington University/Georgia State University

950 New Hampshire Ave NW

Washington, DC 20052

May 2019

Master of Public Health, Health Policy and Management

New York Medical College School of Public Health

40 Sunshine Cottage RD

Valhalla, NY 10595

May 2011

Doctor of Pharmacy

Mercer University School of Pharmacy

3001 Mercer University Dr.

Atlanta, GA 30341

May 2006

Bachelor of Science, Biology

Reinhardt College

7300 Reinhardt College CIR

Waleska, GA 30183

December 2004

Professional Experience:

Centers for Disease Control and Prevention (CDC)

U.S. Department of Health and Human Services

Atlanta, GA

Acting Director (June 2021 - Present)

Deputy Director (May 2020 – Present)

Top Secret/SCI Clearance

National Center for Injury Prevention and Control

Position Description:

- As Acting Director, oversee all leadership and management aspects of the Center, including providing scientific, policy, programmatic, health equity, and management direction of a Center of over 800 FTEs, fellows, and contractors and a budget of more than \$700 million annually.

- As Deputy Director, serve as the primary scientific advisor to the NCIPC Director and other senior CDC staff and provide management and leadership for the Center in collaboration with the Director and the Deputy Director for Management and Operations.
- Oversee the Office of Science, Office of Strategy and Innovation, Office of Informatics, and Overdose Response Coordination Unit.
- Provide scientific and policy counsel on issues in public health, health equity and health disparities, clinical care implementation and payment policy, service delivery, epidemiology, biostatistics, economics, innovative data science and informatics, and strategy.
- Provide focus on critical scientific areas such as: clinical translation and implementation, research methods, analysis, data science innovation, and evaluation relating to assessment of population health needs and health disparities; implementation and effectiveness of policies, interventions, and programs, dissemination of scientific knowledge and information; acquisition and analysis of data for assessing health needs and status (e.g., public health surveillance, data mining, informatics, etc.); new applications and uses of behavioral sciences, community engagement, and multi-level policy and equitable solutions to health needs assessment and intervention.
- Oversee and ensure guidance that all NCIPC scientific research, publications and communications meet the highest standards of scientific quality and integrity and are in accord with all human subjects research protections and other ethical standards.
- Represent CDC in scientific, clinical, and technical meetings, colloquia, and internal CDC, governmental, external venues requiring knowledge and understanding of CDC's activities as well as scientific and programmatic goals and objectives.
- Represent CDC in matters of science in appearances and testimony before Congress, HHS, White House, international forums, and other high-ranking bodies (i.e., WHO, PAHO and ministries of health).
- Collaborates with leaders and scientists in other CDC Centers to coordinate and facilitate strategies, programs and procedures to ensure integration of NCIPC's science with CDC's broader scientific enterprise in particular in areas of drug overdose, substance use and mental health, suicide prevention, and adverse childhood experiences.
- Lead and participate in interagency and nongovernmental working groups and collaboratives on injury and violence prevention.
- Conduct epidemiological, clinical, and policy research on substance use, mental health, overdose, suicide, and other violence and injury topics to improve policy, programs, and clinical practice.
- Routinely engage with key policy and public health organizations such as the National Governors Association, Association of State and Territorial Health Officials, Mental Health America (MHA), National Association of State Alcohol and Drug Abuse Directors, National Association of City and County Health Officials, the National League of Cities, National Association of Counties, and Council of State and Territorial Epidemiologists.
- Engage with healthcare professional society leaders and professional societies such as the American Medical Association (AMA), key policy and scientific convenings by the National Academy of Medicine (NAM), among others to advance research, public health, and clinical practice initiatives and innovations.
- Engage with Executive Branch agencies, including the Domestic Policy Council, National Security Council, Office of Management and Budget, Office of National Drug Control Policy, Departments of State, Justice, Defense, and Veterans Affairs, among others, to advance a range of public health issues.
- Routinely Brief Members of Congress and their staff.
- Provide media interviews, including to international, national, and state media outlets.
- Routinely present at international, national, and state meetings.
- Participate in emergency response activities in support of CDC's mission – Incident Manager and Deputy Incident Manager of the CDC Emergency Response on Vaping and Lung Injury, working closely with FDA leadership and incident management system. Served in multiple COVID-19 response roles.

Centers for Disease Control and Prevention (CDC)
U.S. Department of Health and Human Services
Atlanta, GA

Senior Advisor & Associate Director, Office of Strategy & Innovation,
National Center for Injury Prevention and Control
Sept 2018-May 2020

Position Description:

- Serve as senior advisor to the Injury Center Director and provide public health counsel on priority injury and violence prevention topics.
- Provide strategic policy and scientific direction and coordination on overdose, suicide, and adverse childhood experiences (ACEs), among other priority topics in the Injury Center.
- Provide leadership for strategic planning and development of innovations across Injury Center programs.
- Work with Offices and Divisions to develop and maintain ongoing mechanisms for obtaining ideas, initiatives, and concerns in the development of state and national programs, policies, and practices related to injury and violence topics, with a focus on Injury Center strategic priorities – ACEs, suicide, and opioid overdose prevention.
- Lead a team of scientist and public health practitioners to advance innovative approaches to using data to inform prevention efforts, and expand the use of data science tools, methods, and techniques across Injury Center programs.
- Build strategic partnerships to advance public health data and surveillance, and the deployment of data science innovations in the injury and violence prevention field.
- Participate in and lead interagency and nongovernmental working groups and collaboratives on injury and violence prevention.
- Conduct epidemiological and policy research to improve policy, programs, and clinical practice.
- Serve as CDC representative on substance use and overdose initiatives, ACEs prevention, and suicide prevention within Federal Work Groups.
- Engage with healthcare professional society leaders and professional societies to advance clinical practice initiatives and innovations.
- Engage with national, state, and local public health organizations, national, state, and local associations, and other external stakeholders to advance policy, program, and practice change.
- Brief Members of Congress and their staff.
- Provide media interviews.
- Routinely present at international, national, and state scientific meetings.
- Participate in emergency response activities in support of CDC's mission – Incident Manager and Deputy Incident Manager of the CDC Emergency Response on Vaping and Lung Injury, working closely with FDA leadership and incident management system.

Substance Abuse and Mental Health Services Administration (SAMHSA)
U.S. Department of Health and Human Services
Rockville, MD
Director
National Mental Health and Substance Use Policy Laboratory
Jan 2018-Sept 2018

Position Description:

- Appointed as the first director of the National Mental Health and Substance Use Policy Laboratory created by Congress in the 21st Century Cures Act of 2016.
- Oversee the development and implementation of the Policy Laboratory, including developing and managing budget, hiring and mentoring staff, and setting priorities for the Lab.
- Oversee all aspects of the Policy Laboratory, including identifying, coordinating, and facilitating the implementation of policies that will have a significant effect on mental health, mental illness (especially severe mental illnesses such as schizophrenia and schizoaffective disorders), suicide prevention, adverse childhood experiences (ACEs), recovery supports, and the prevention and treatment of substance use disorders.
- Promote evidence-based practices and service delivery models and give preference to models that improve the coordination between mental health and physical health providers; the coordination among such providers and the justice and corrections system; and the cost effectiveness, quality, effectiveness, and efficiency of health care services furnished to adults with a serious mental illness, children with a serious emotional disturbance, or individuals in a mental health crisis.
- Lead the development of the Evidence-Based Practices Resource Center, a national repository of evidence-based practices, programs, and policies related to substance use, mental health, and suicide.
- Work collaboratively with SAMHSA leadership and leadership in other Federal agencies to identify priority areas related to research and implementation of evidence-based policies, practices, programs, and clinical service delivery models related to the prevention, treatment, and recovery from mental and substance use disorders.
- Maintain an active research and policy portfolio on mental health and substance use.
- Advise the Assistant Secretary for Mental Health and Substance Use on behavioral health and policy issues and strategic direction of the agency.
- Provide leadership for strategic planning and the development of innovations and reform in SAMHSA and the fields of mental health and substance use. Work with Centers and Offices to develop and maintain ongoing mechanisms for obtaining ideas, initiatives, and concerns in the development of state and national program policies with respect to Presidential/Department initiatives and Agency programs.
- Seek input from a broad range of stakeholders in forecasting policy needs and developing policy positions.
- Lead the preparation of SAMHSA's Strategic Plan FY2019-FY2023 published in November 2018.
- Maintain liaison and represent the Assistant Secretary in meetings with HHS, with other Federal agencies, Congressional committees, and private organizations concerning behavioral health policy.
- Provide executive leadership, managerial direction, and supervision to professional, scientific, technical, and support personnel engaged in a variety of broad substantive issues related to policy and program coordination, implementation, and evaluation.
- Formulate recommendations to the Assistant Secretary regarding policy and its implementation, including resolving policy issue differences on behalf of the Assistant Secretary.
- Work with the Center for Behavioral Health Statistics and Quality at SAMHSA to collect, as appropriate, information from grantees under programs operated by the Administration in order to evaluate and disseminate information on evidence-based practices and service delivery models.
- Work with the Center for Behavioral Health Statistics and Quality at SAMHSA to develop new surveillance systems and enhance existing surveillance systems to improve understanding of substance use and mental health and inform the delivery of clinical and community-based services.
- Provide leadership in identifying and coordinating policies and programs, including evidence-based programs, related to mental and substance use disorders.
- Brief Members of Congress and their staff.
- Provide media interviews as requested.
- Routinely present on substance use and mental health at international, national, and state meetings.

**Office of the Assistant Secretary for Planning and Evaluation (ASPE)
U.S. Department of Health and Human Services
Washington, DC**

**Acting Associate Deputy Assistant Secretary for Science and Data Policy
December 2016-December 2017**

**Director, Division of Science Policy
September 2015-December 2017**

Position Description:

- As Acting Associate Deputy Assistant Secretary, provide scientific and policy leadership for the Office of Science and Data Policy, including:
 - Oversee the budget and research planning and execution of the research agenda for the Office of Science and Data Policy; manage staff, provide oversight on hiring and meeting ASPE objectives for the Office.
 - Oversee the Division of Data Policy which is responsible for data and statistical policy development and coordination within HHS and serves as the HHS focal point for department-wide data and statistical policy. The Division provides leadership and staff support to the HHS Data Council, the principal internal forum and advisory body to the Secretary on data policy issues, including data collection strategy, statistical policy, data standards, and informatics issues.
 - Oversee the Division of Science Policy which is the ASPE lead on public health and biomedical science policy issues and initiatives, including programmatic and policy areas that involve complex or rapidly evolving science and technology. The Division provides technical assistance on regulatory impact analysis development to HHS agencies and offices. The Division is responsible for policy coordination; long-range planning; legislative development; economic, program, and regulatory analysis and research; and evaluation focused on the HHS science agencies – the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and Office of the Assistant Secretary for Preparedness and Response (ASPR).
 - Oversee the Strategic Planning Team leads the development of the HHS Strategic Plan, ensuring that it reflects the activities that HHS is undertaking over the next four years. The Team aligns the HHS Strategic Plan's goals and objectives with our Priority Goals, the Secretary's priorities, and other, topic-specific strategic plans implemented by the Department. The Team integrates performance measurement, program integrity and risk management, research and evaluation, and budget information into topic-specific strategic plans to ensure that they are ambitious, but achievable, and that threats to performance and goal achievement can be identified and mitigated quickly.
- Provide policy counsel and strategic advice to HHS Senior Leaders, including the HHS Secretary and Senior Counselors, and lead the development and implementation of Administration and HHS-level initiatives.
- Oversee the Department's legislative and policy development process related to the HHS science agencies the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and Office of the Assistant Secretary for Preparedness and Response (ASPR).
- Engage with the White House Domestic Policy Council, Office of Science and Technology Policy, and National Security Council on priority science, regulatory, and public health policy issues.
- As Division Director, responsible for the direct leadership, management, and supervision of the Division. The Division is the HHS lead on public health and biomedical science issues and initiatives, including programmatic and policy areas that involve complex or rapidly evolving science and technology. The Division is responsible for policy coordination; long-range planning; legislative development; economic, program, and regulatory analysis; and evaluation focused on the HHS science agencies.

- Provide science and public health policy counsel and recommendations to Senior Leaders in HHS, including the Secretary, on priority public health policy issues and initiatives.
- Oversee the conduct of epidemiological, pharmacoepidemiological, and health economic research related to prescription drug safety, effectiveness, and economic impact; drug utilization pricing and trends; and incentives for drug and other medical product development.
- Serve as co-chair of the Administration's Combatting Antibiotic Resistant Bacteria Task Force leading and coordinating policy and programmatic initiatives across multiple Departments and Agencies across the Executive Branch.
- Oversee scientific policy review of NIH, FDA, CDC, and ASPR budget and legislative proposals.
- Maintain an active research and policy portfolio on substance use and overdose.
- Engage with healthcare professional societies, state government associations, and external stakeholders to advance policy and practice change. This requires a deep understanding of multiple topics as well as the ability to communicate effectively with a broad range of stakeholders, often with divergent viewpoints.
- Serve as Senior HHS lead subject matter expert on substance use and overdose, with a particular focus on the opioid epidemic.
- HHS Policy Lead, National Security Council Transnational Organized Crime Interagency Policy Committee
- Provide scientific oversight to a large and diverse staff that includes medical officers, health economists, policy analysts, lawyers, researchers, and public health practitioners. Staff range from GS-11 to GS 15 or PHS Commissioned Corps O-6.
- Mentor staff on job performance, professional development, and opportunities to engage with partners inside and external to HHS on issues as diverse as medical product innovation and development, domestic and international preparedness and response, regulatory impact analysis, drug utilization and cost trends, and opioid overdose prevention, among others.
- Develop, fund, and carry out research agenda on science policy-related issues, in collaboration with NIH, CDC, FDA, and ASPR.
- Regularly present at international, national, and state meetings.
- Regularly brief Members of Congress and their staff.
- Regularly provide media interviews.

**U.S. Food and Drug Administration
U.S. Department of Health and Human Services
Silver Spring, MD**

**Senior Advisor
Office of the Commissioner
February 2014-September 2015**

Position Description:

- Serve as senior advisor to the Associate Commissioner and Commissioner on priority public health topics and provide public health counsel and recommendations to Agency leadership.
- Provide strategic policy direction and analysis on a range of public health topics to the FDA Commissioner and senior FDA leadership. This included coordinating cross-FDA and cross-HHS activities related to strategic policy and budget planning. Specific initiatives included FDA's precision medicine initiative, laboratory developed tests, Next Generation Sequencing, review of power morcellators and uterine cancer, opioid and other controlled prescription drug abuse, food safety initiatives, and modified-risk tobacco product regulatory actions.
- Conduct quantitative epidemiological, economic, and policy research related to FDA regulated products and public health matters, including approaches to drug safety and risk management.

- Develop and carry out a research agenda to further understand prescription drug misuse and overdose risk factors and evaluate the impact of FDA policies and regulations.
- Serve as a core member of the FDA Precision Medicine working group to develop the Agency's regulatory approach to Precision Medicine as part of the Administration's Precision Medicine Initiative.
- Engaged with FDA regulatory Centers (drugs, biologics, devices, food and cosmetics, tobacco) to identify priority public health issues for further analyses to inform regulatory decision making.
- Serve as Agency lead on substance use and overdose and lead Agency's opioid abuse workgroup. This required extensive interaction and strategic leadership across a diverse group of senior Agency leaders.
- Serve as FDA representative on drug abuse and overdose work within Federal Interagency Work Groups.
- Engage with healthcare professional society leaders, national and state associations, and other external stakeholders to advance policy and practice change. This requires a deep understanding of multiple topics as well as the ability to communicate effectively with a broad range of stakeholders, often with divergent viewpoints.
- Write scientific articles for publication in peer-reviewed journals.
- Brief Members of Congress and their staff on a regular basis.
- Provide media interviews as requested.
- Present on FDA public health issues at international, national, and state meetings.

**Centers for Disease Control and Prevention
U.S. Department of Health and Human Services
Atlanta, GA**

**Senior Scientist, Team Leader
Prescription Drug Overdose Team
July 2011-February 2014**

Position Description:

- Serve as CDC lead on substance use, misuse, and overdose.
- Provide strategic policy direction on substance use and overdose to the CDC Director and senior CDC leadership.
- Develop CDC's drug overdose program, including interviewing and hiring staff, identifying budget resources and priorities, securing funding for priority projects and programs.
- Develop and carry out a scientific research agenda to further identify substance use risk factors, evaluate policies and programs at the federal, state, and local level, and enhance surveillance activities.
- Conducted epidemiological and evaluation research to improve policy and clinical practice.
- Manage a budget and staff related to CDC's drug overdose program.
- Engage in strategic policy development and implementation at the national, state, and local level with a broad range of public and private stakeholders.
- Participate in legislative and stakeholder development, technical assistance, and outreach.
- Provide direct technical assistance to state leadership on strategic policy planning, research, and evaluation activities related to substance abuse and overdose.
- Serve as a lead for CDC on drug abuse and overdose work within Federal Interagency Work Groups.
- Engage with healthcare professional society leaders on various policy and practice issues.
- Wrote scientific articles for publication in peer-reviewed journals.
- Brief Members of Congress and their staff regularly.
- Present on substance abuse at national and state meetings.
- Provide media interviews as requested.

**White House Office of National Drug Control Policy
Executive Office of the President of the United States
Washington, DC**

**Senior Public Health Advisor
Office of the Director
August 2010-July 2011 (1 year detail assignment)**

Position Description:

- Provide public health counsel to the Director of ONDCP and Departmental and Agency leadership regarding substance use policy, research, surveillance, and legislative issues.
- Co-lead the development of the President's Prescription Drug Abuse Prevention Plan – the Federal Government roadmap for preventing prescription drug abuse.
- Serve as policy lead for Active Duty, Veterans, and Military Family issues related to substance use.
- Analyze and draft policy documents and briefing materials on various policy and legislative efforts related to the President's National Drug Control Strategy.
- Conduct quantitative and qualitative epidemiological, clinical practice, and policy research to inform national drug policy.
- Brief and meet with senior leadership of federal agencies and Members of Congress and their staff in order to advance the President's drug control policies and strategy.
- Engage with external stakeholders to further the President's National Drug Control Strategy.
- Engage in cross-Agency budget development process to advance the President's drug control program.
- Contribute to the development of the National Drug Control Strategy.

**U.S. Food and Drug Administration
U.S. Department of Health and Human Services
Silver Spring, MD**

**Team Leader
Center for Drug Evaluation and Research
December 2008-August 2010**

Position Description:

- Develop strategic direction and policy for FDA's public communications on drug safety and risk.
- Work closely with the Office of Surveillance and Epidemiology and Pharmacovigilance Divisions to synthesize drug safety and risk management information to inform regulatory decisions by CDER.
- Conduct pharmacoepidemiological research related to drug safety and risk mitigation and evidence-based strategies to communicate risk information to healthcare providers, patients, and the general public.
- Supervise two GS-14 science policy analysts, one 0-5 Commissioned Corps pharmacist (in an 0-6 billet) and one GS-13 pharmacist.
- Work across multiple offices within CDER and with FDA and CDER Senior Management to develop, monitor, and improve FDA's communications concerning new and emerging drug safety and risk management issues.
- Serve as H1N1 communication coordinator for CDER. Responsible for drafting H1N1 communications and coordinating communications between FDA, CDC, and HHS.
- Engage with external stakeholders to improve dissemination and penetration of FDA's drug safety and risk management messages.

**Catalyst Rx
Atlanta, GA**

Clinical Pharmacist, April 2007-June 2008

Position Description:

- Provide clinical pharmacy management and oversight for the Southeastern office of CatalystRx. This included management responsibilities across multiple divisions within the office.
- Provide strategic clinical direction for individual clients.
- Develop clinical and education programs to address medication adherence and compliance for chronic conditions such as substance use disorder, HIV, hyperlipidemia, hypertension, heart failure, asthma, mental health conditions, and financial costs of drug therapy management.
- Conduct pharmacoepidemiological and economic analyses to monitor medication use and cost trends, and to identify emerging therapeutic issues. Responsible for the management of over \$100 million dollars in drug spend.
- Serve as voting member of the CatalystRx National Pharmacy and Therapeutics committee.
- Give large-scale physician educational presentations on appropriate use of medications.
- Provide one on one physician education to address patient compliance, cost savings, and therapeutic interchange opportunities.
- Create drug monographs and clinical updates on new medications for presentation to clients and pharmacy and therapeutic committees.
- Analyze the clinical literature in order to present clear guidance to pharmacy and therapeutics committee as well as clients for pharmacy benefit decision making.

**Centers for Disease Control and Prevention
U.S. Department of Health and Human Services
Lockheed Martin Information Technology – contractor
Atlanta, GA**

**Pharmacist
Strategic National Stockpile, Science Team
April 2006-April 2007**

Position Description:

- Work with federal, state, local public health officials to help them understand the capabilities and role of the Strategic National Stockpile (SNS).
- Serve as member of the CDC Pandemic Influenza Task Force-responsible for developing CDC operational plan and SNS response during a pandemic influenza.
- Serve as science team representative during CDC and SNS exercises and real-world responses.
- Develop and manage the formulary for the SNS.
- Conduct reviews of the scientific literature and provide scientific input into epidemiological and clinical practice studies related to pharmaceutical products being proposed for placement in the stockpile or for novel therapeutic agents under development.
- Present to Federal, State, Local public health officials on the science behind products and how and when to use countermeasures in the stockpile.
- Represent the SNS on CDC wide working groups: Smallpox, Chronic disease and vulnerable populations in times of natural disaster, SNS V10 working group.

National Capital Poison Center – On Call Staffing
Washington, DC
Clinical Pharmacist
February 2009-July 2011

Position Description:

- Answer and respond to intentional and unintentional exposures to medications, chemicals, toxins, food-borne illness, and other public health emergencies.
- Develop a plan of treatment for healthcare providers and the lay public for exposure based on clinical judgment, literature review, and toxicity data of the product.
- Interact with various government agencies (public health, fire, ems, police) in organizing an appropriate response to toxicologic emergencies.
- Poison prevention educational presentations.

Georgia Poison Center – On Call Staffing
Grady Health System
Atlanta, GA
Clinical Pharmacist
Certified Specialist in Poison Information
June 2003 – December 2008

Position Description:

- Answer and respond to intentional and unintentional exposures to medications, chemicals, toxins, food-borne illness, and other public health emergencies.
- Develop a plan of treatment for healthcare providers and the lay public for exposure based on clinical judgment, literature review, and toxicity data of the product.
- Interact with various government agencies (public health, fire, ems, police) in organizing an appropriate response to toxicologic emergencies.
- Poison prevention educational presentations

Peer-Reviewed Publications:

2022

- **Jones CM**, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the United States before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. 2022. JAMA. Under Review
- **Jones CM**, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM. Receipt of telehealth services, receipt and retention on medications for opioid use disorder, and nonfatal drug overdose among Medicare beneficiaries before and during the COVID-19 pandemic. 2022. JAMA. Under Review
- **Jones CM**, Han B, Seth P, Baldwin G, Compton WM. Increases in methamphetamine injection among treatment admissions. 2022. Drug Alcohol Depend. Under Review.
- Hall EW, Rosenberg ES, **Jones CM**, Asher A, Valverde E, Bradley H. Estimated number of injection-involved drug overdose deaths, United States, 2000-2018. Drug Alcohol Depend. 2022;234:109428.
- Compton WM, Einstein EB, **Jones CM**. Exponential increases in drug overdose: implications for epidemiology and research. Int J Drug Policy. 2022. In press
- Brener ND, Bohm MK, **Jones CM**, et al. Use of tobacco products, alcohol, and other substances among high school students during the COVID-19 Pandemic – Adolescent Behaviors and Experiences Survey, United States, January-June 2021. MMWR Suppl. 2022;71(3):8-15.

- Sarker A, Nataraj N, Sui W, Li S, **Jones CM**, Sumner SA. Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts. *Subst Abuse Treat Prev Policy*. 2022;17(1):16.
- Seitz AE, Janiszewski KA, Guy GP, Tapscott RT, Einstein EB, Meyer TE, Tierney J, Staff J, **Jones CM**, Compton WM. Evaluating opioid analgesic prescribing limits: A narrative review. *Pharmacoepidemiol Drug Saf*. 2022. Mar 5.
- Ehlman DC, Yard E, Stone DM, **Jones CM**, Mack KA. Changes in suicide rates- United States, 2019 and 2020. *MMWR Morb Mortal Wkly Rep*. 2022;71(8):306-312.
- ElSherief M, Sumner SA, **Jones CM**, Law RK, Kacha-Ochana A, et al. Characterizing and identifying the prevalence of web-based misinformation relating to medication for opioid use disorder: Machine Learning Approach. *J Med Internet Res*. 2021;23(12):e30753.

2021

- **Jones CM**, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. *Ann NY Acad Sci*. 2021. Sep24. Doi:10.1111/nyas.14688.
- Jiang X, Guy GP, Dunphy C, Pickens CM, **Jones CM**. Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019. *Drug Alcohol Depend*. 2021. Oct 30;229(Pt A):109160.
- Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handangic S, **Jones CM**, McClung RP, Asher AK. Syringe services programs' role in ending the HIV Epidemic in the U.S.: Why we cannot do it without them. *Am J Prev Med*. 2021.61(5 Suppl 1):S118-S129.
- Han B, **Jones CM**, Einstein EB, Compton WM. Trends in and characteristics of buprenorphine misuse among adults in the U.S. *JAMA Netw Open*. 2021;4(1):e2129409.
- Dunphy C, Zhang K, Guy GP, **Jones CM**. Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018. *Prev Med*. 2021;153:106820.
- Han B, Compton WM, **Jones CM**, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. *JAMA Psychiatry*. 2021. Sep 22.doi: 10.1001/jamapsychiatry.2021.2588.
- Sumner SA, Ferguson B, Bason B, Dink J, Yard E, Hertz M, Hilkert B, Holland K, Mercado-Crespo M, Tang S, **Jones CM**. Association of online risk factors with subsequent youth suicide-related behaviors in the U.S. *JAMA Netw Open*. 2021. Sep1;4(9):e2125860.
- **Jones CM**, Diallo MM, Vythilingam M, Schier JG, Eisenstat M, Compton WM. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. *Drug Alcohol Depend*. 2021;225:108783.
- Compton WM, **Jones CM**. Substance use among men who have sex with men. *N Engl J Med*. 2021;385(4):352-356.
- Han B, **Jones CM**, Einstein EB, Powell PA, Compton WA. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. *JAMA Psychiatry*. 2021;78(8):922-924.
- Trivers KF, Watson CV, Neff LJ, **Jones CM**, Hacker K. Tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, product use behaviors among adults after the onset of the 2019 outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI). *Addict Behav*. 2021;121:106990.
- Dunphy C, Peterson C, Zhang K, **Jones CM**. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? *Drug Alcohol Depend*. 2021;225:108784.
- Wright AP, **Jones CM**, Chau DH, Gladden MR, Sumner SA. Detection of emerging drugs involved in overdose via diachronic word embeddings of substances discussed on social media. *J Biomed Inform*. 2021;119:103824.

- Mustaquim D, **Jones CM**, Compton WM. Trends and correlates of cocaine use among adults in the United States, 2006-2019. *Addict Behav.* 2021;120:106950.
- Tang S, **Jones CM**, Wisdom A, Lin HC, Bacon S, Houry D. Adverse childhood experiences and stimulant use disorders among adults in the United States. *Psychiatry Res.* 2021;299:113870.
- Guy GP, Strahan AE, Haegerich T, Losby JL, Ragan K, Evans ME, **Jones CM**. Concurrent naloxone dispensing among individuals with high-risk opioid prescriptions, USA, 2015-2019. *J Gen Intern Med.* 2021 Mar 9. Doi:10.1007/s11606-021-06662-3.
- Wilkins NJ, Clayton HB, **Jones CM**, Brown M. Current prescription opioid misuse and suicide risk behaviors among high school students. *Pediatrics.* 2021;147(4):e2020030601.
- Stone DM, **Jones CM**, Mack KA. Changes in suicide rates – United States, 2018-2019. *MMWR Morb Mortal Wkly Rep.* 2021;70(8):261-268.
- **Jones CM**, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. *Epidemiol Rev.* 2021;42(1):154-166.
- Stein BD, Smart R, **Jones CM**, Sheng F, Powell D, Sorbero M. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. *J Gen Intern Med.* 2021. Feb 17. Online ahead of print.
- Stein BD, **Jones CM**, Smart R, Sheng F, Sorbero M. Patient, prescriber, and community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18. *Drug Alcohol Depend.* 2021. Feb3. Online ahead of print.
- **Jones CM**, Board AR, Guy G. Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. *Drug Alcohol Depend.* 2021;219:108846.
- Holland KM, **Jones CM**, Vivolo-Kantor AM, Idaikkadar N, Zwald M, Hoots B, et al. Trends in U.S. emergency department visits for mental health, overdose, and violence-related outcomes before and during the COVID-19 pandemic. *JAMA Psychiatry.* 2021;78(4):372-379.

2020

- King BA, **Jones CM**, Baldwin GT, Briss PA. E-cigarette, or vaping, product use-associated lung injury: looking back, moving forward. *Nicotine Tob Res.* 2020;22(Supplement_1):S96-S99.
- Vivolo-Kantor AM, Hoots BE, Seth P, **Jones CM**. Recent trends and associated factors of amphetamine-type stimulant overdoses in emergency departments. *Drug Alcohol Depend.* 2020;216:108323.
- Board AR, Guy G, **Jones CM**, Hoots B. Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty – United States, 2014-2019. *Drug Alcohol Depend.* 2020;217:108297.
- **Jones CM**, Clayton HB, Deputy NP, Roehler DR, Ko JY, et al. Prescription opioid misuse and use of alcohol and other substances among high school students – Youth Risk Behavior Survey, United States, 2019. *MMWR Suppl.* 2020;69(1):38-46.
- **Jones CM**, Noonan RK, Compton WM. Prevalence and correlates of ever having a substance use problem and substance use recovery status among adults in the United States, 2018. *Drug Alcohol Depend.* 2020 Sep 1;214:108169.
- Sumner SA, Haegerich TM, **Jones CM**. Temporal trends in online posts about vaping of cannabis products. *J Addict Med.* 2020. Aug 4. Online ahead of print.
- Allen ST, Grieb SM, White RH, O'Rourke A, Kilkenny ME, **Jones CM**, Latkin C, Sherman SG. Human Immunodeficiency Virus testing among people who inject drugs in rural West Virginia. *J Infect Dis.* 2020;222(Supplement_5):S346-S353.
- Levitt A, Mermin J, **Jones CM**, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. *J Infect Dis.* 2020;222(Supplement_5):S213-S217.

- Roehler DR, Guy GP, **Jones CM**. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. *Drug Alcohol Depend.* 2020. May 25;213:108083. doi: 10.1016/j.drugalcdep.2020.108083. Online ahead of print
- Reagan-Steiner S, Matkovic GJ, Ritter JM, Shieh WJ, Martines RB, Werner AK, Lynfield R, Holzbauer S, Bullock H, Denison AM, Bhatnager J...**Jones CM**, et al. Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series. *Lancet Respir Med.* 2020;Aug4:S2213-2600.
- Werner AK, Koumans EH, Chatham-Stephens K, Salvatore PP, Armatas C, Byers P, Clark CR, Ghinai I, Holzbauer SM, Navarette KA, Danielson ML, Ellington S, Moritz ED, Petersen EE, Kiernan EA, Baldwin GT, Briss P, **Jones CM**, et al. Hospitalizations and deaths associated with EVALI. *N Engl J Med.* 2020;382(17):1589-1598.
- Adkins SH, Anderson KN, Goodman AB, Twentyman E, Danielson ML, Kimball A, Click ES, Ko JY, Evans ME, Weissman DN, Melstrom P, Kiernan E, Krishnasamy V, Rose DA, **Jones CM** et al., Demographics, substance use behaviors, and clinical characteristics of adolescents with e-cigarette, or vaping, product use-associated lung injury (EVALI) in the United States in 2019. *JAMA Pediatr.* 2020. 174(7):e200756.
- **Jones CM**, Mustaquim D, Compton WM. Patterns and correlates of methamphetamine use among adults in the United States, 2015-2018. *MMWR Morb Mortal Wkly Rep.* 2020;69(12):317-323.
- Compton WM, **Jones CM**. Commentary on Chan & Hall (2020): Advances in specifying cannabis consumption. *Addiction.* 2020;115(6):1187-1188.
- Smart R, Geiger CK, **Jones CM**, Stein BD. Prescribers and naloxone pharmacy claims. *J Gen Intern Med.* 2020. Mar 24. doi:10.1007/s11606-020-05791-5.
- **Jones CM**, Olsen EO, O'Donnell J, Mustaquim D. Resurgent methamphetamine use at treatment admission in the United States, 2008-2017. *Am J Pub Health.* 2020;110(4):509-516.
- King BA, **Jones CM**, Baldwin GT, Briss PA. The EVALI and Youth-Vaping Epidemics — Implications for Public Health. *N Engl J Med.* 2020;382(8):689-691.
- Compton WM, **Jones CM**, Underwood N. Reducing negative consequences from use of methamphetamine. *Addiction.* 2020;115(6):1190-1191.
- Krishnasamy VP, Hollowell BD, Ko JY, Board A, Hartnett KP, Salvatore PP, Danielson M, Kite-Powell A, Twentyman E, Kim L, Cyrus A, Wallace M, Melstrom P, Haag B, King BA, Briss P, **Jones CM**, et al. Update: Characteristics of a nationwide outbreak of E-cigarette, or vaping, product use-associated lung injury – United States, August 2019-January 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(3):90-94.
- Ghinai I, Navon L, Gunn JKL, Duca LM, Brister S, Love S, Brink R, Fajardo G, Johnson J, Saathoff-Huber L, King BA, **Jones CM**, Krisnasamy VP, Layden JE. Characteristics of persons who report using only nicotine-containing products among interviewed patients with E-cigarette, or vaping, product use-associated lung injury – Illinois, August-December 2019. *MMWR Morb Mortal Wkly Rep.* 2020;69(3):84-89.
- Ellington S, Salvatore PP, Ko J, Danielson M, Kim L, Cyrus A, Wallace M, Board A, Krishnasamy V, King BA, Rose D, **Jones CM**, Pollack LA et al. Update: product, substance-use, and demographic characteristics of hospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury – United States, August 2019-January 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jan 17;69(2):44-49.

2019

- **Jones CM**, Merrick MT, Houry DE. Identifying and preventing adverse childhood experiences: implications for clinical practice. *JAMA.* 2019 Nov 5. Doi:10.1001/jama.2019.18499. [Epub ahead of print].
- **Jones CM**, Byrd DJ, Clarke TJ, Campbell TB, Ohuoha C, McCance-Katz EF. Characteristics and current clinical practices of opioid treatment programs in the United States. *Drug Alcohol Depend.* 2019;205:107616.

- **Jones CM**, Underwood JM, Volkow ND. Challenging the association of marijuana laws with teen marijuana use. *JAMA Pediatr.* 2019 Nov 11. Doi:10.1001/jamapediatrics.2019.4235. [Epub ahead of print].
- Madras BK, Han B, Compton WM, **Jones CM**, Lopez EI, McCance-Katz EF. Associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use, and opioid misuse. *JAMA Netw Open.* 2019;2(11):e1916015.
- Mikosz CA, Danielson M, Anderson KN, Pollack LA, Currie DW, Njai R, Evans ME, Goodman AB, Twentyman E, Wiltz JL, Rose DA, Krishnasamy V, King BA, **Jones CM**, et al. Characteristics of patients experiencing rehospitalization or death after hospital discharge in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury – United States, 2019. *MMWR Morb Mortal Wkly Rep.* 2020;68(5152):1183-1188.
- Evans ME, Twentyman E, Click ES, Goodman AB, Weissman DN, Kiernan E, Hocevar SA, Mikosz CA, Danielson M, Anderson KN, Ellington S, Lozier MJ, Pollack LA, Rose DA, Krishnasamy V, **Jones CM**, et al. Update: interim guidance for health care professionals evaluating and caring for patients with suspected e-cigarette, or vaping, product use-associated lung injury and for reducing the risk for rehospitalization and death following hospital discharge – United States, December 2019. *MMWR Morb Mortal Wkly Rep.* 2020;68(5152):1189-1194.
- Blount BC, Karwowski MP, Shields PG, Morel-Espinosa M, Valentin-Blasini L, Gardner M, Braselton M, Brosius CR, Caron KT, Chambers D, Corstvet J, Cowan E, De Jesús VR, Espinosa P, Fernandez C, Holder C, Kuklenyik Z, Kusovschi JD, Newman C, Reis GB, Rees J, Reese C, Silva L, Seyler T, Song MA, Sosnoff C, Spitzer CR, Tevis D, Wang L, Watson C, Wewers MD, Xia B, Heitkemper DT, Ghinai I, Layden J, Briss P, King BA, Delaney LJ, **Jones CM**, et al. Vitamin E acetate in bronchoalveolar lavage fluid associated with EVALI. *N Engl J Med.* 2019 Dec 20. Doi:10.1056/NEJMoa1916433. [Epub ahead of print].
- Lozier MJ, Wallace B, Anderson K, Ellington S, **Jones CM**, Rose D, Baldwin G, King BA, Briss P, Mikosz CA. Update: demographic, product, and substance-use characteristics of hospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injuries – United States, December 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(49):1142-1148.
- Chatham-Stephens K, Roguski K, Jang Y, Cho P, Jatlaoui TC, Kabbani S, Glidden E, Ussery EN, Trivers KF, Evans ME, King BA, Rose DA, **Jones CM**, et al. Characteristics of hospitalized and nonhospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury – United States, November 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(46):1076-1080.
- Jatlaoui TC, Wiltz JL, Kabbani S, Siegel DA, Koppaka R, Montandon M, Adkins SH, Weissman DN, Koumans EH, O'Hegarty M, O'Sullivan MC, Ritchey MD, Chatham-Stephens K, Kiernan EA, Layer M, Reagan-Steiner S, Legha JK, Shealy K, King BA, **Jones CM**, et al. Update: interim guidance for health care providers for managing patients with suspected e-cigarette, or vaping, product use-associated lung injury – United States, November 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(46):1081-1086.
- Navon L, **Jones CM**, Ghinai I, King BA, Briss PA, Hacker KA, Layden JE. Risk factors for e-cigarette, or vaping, product use-associated lung injury (EVALI) among adults who use e-cigarette, or vaping, products – Illinois, July-October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(45):1034-1039.
- Blount BC, Karwowski MP, Morel-Espinosa M, Rees J, Sosnoff C, Cowan E, Gardner M, Wang L, Valentin-Blasini L, Silva L, De Jesus VR, Kuklenyik Z, Watson C, Seyler T, Xia B, Chambers D, Briss P, King BA, Delaney L, **Jones CM**, et al. Evaluation of bronchoalveolar lavage fluid from patients in an outbreak of e-cigarette, or vaping, product use-associated lung injury – 10 states, August-October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(45):1040-1041.
- **Jones CM**, Underwood N, Compton W. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-2017. *Addiction.* 2019. Doi:10.1111/add.14812.
- Merrick MT, Ford DC, Ports KA, Guinn AS, Chen J, Klevens J, Metzler M, **Jones CM**, Simon TR, Daniel VM, Ottley P, Mercy JA. Vital Signs: estimated proportion of adult health problems attributable to adverse

- childhood experiences and implications for prevention – 25 states, 2015-2017. *MMWR Morb Mortal Wkly Rep.* 2019;68(44):999-1005.
- Moritz ED, Zapata LB, Lekiachvili A, Glidden E, Annor FB, Werner AK, Ussery EN, Hughes MM, Kimball A, DeSisto CL, Kenemer B, Shamout M, Garcia MC, Regan-Steiner S, Petersen EE, Koumans EH, Ritchet MD, King BA, **Jones CM**, et al. Update: Characteristics of patients in a national outbreak of e-cigarette, or vaping, product use-associated lung injuries – United States, October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(43):985-989.
 - Lippold KM, **Jones CM**, Olsen EO, Giroir BP. Racial/ethnic and age group differences in opioid and synthetic opioid-involved overdose deaths among adults aged ≥ 18 years in metropolitan areas – United States, 2015-2017. *MMWR Morb Mortal Wkly Rep.* 2019;68(43):967-973.
 - Smart R, Geiger CK, **Jones CM**, Stein BD. An observational study of retail pharmacy naloxone prescriptions: differences across provider specialties and patient populations. *J Gen Intern Med.* 2019. Doi:10.1007/s11606-019-05448-y.
 - Siegel DA, Jatlaoui TC, Koumans EH, Kiernan EA, Layer M, Cates JE, Kimball A, Weissman DN, Petersen EE, Reagan-Steiner S, Godfred-Cato S, Moulja D, Moritz E, Lehnert JD, Mitchko J, London J, Zaki SR, King BA, **Jones CM**, et al. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury – United States, October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(41):919-927.
 - Perrine CG, Pickens CM, Boehmer TK, King BA, **Jones CM**, DeSisto CL, Duca LM, Lekiachvili A, et al. Characteristics of a multistate outbreak of lung injury associated with e-cigarette use, or vaping – United States, 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(39):860-864.
 - Haegerich TM, **Jones CM**, Cote PO, Robinson A, Ross L. Evidence for state, community, and systems-level prevention strategies to address the opioid crisis. *Drug Alcohol Depend.* 2019;204:107563.
 - **Jones CM**, Warner M, Hedegaard H, Compton W. Data quality considerations when using county-level opioid overdose death rates to inform policy and practice. *Drug Alcohol Depend.* 2019;204:107549.
 - **Jones CM**, Compton WM, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving prescription opioids in the Medicare Part D program, United States, 2016-2017. *JAMA* 2019;322(5):462-464.
 - Guy GP, Haegerich TM, Evans ME, Losby JL, Young R, **Jones CM**. Vital Signs: pharmacy-based naloxone dispensing – United States, 2012-2018. *MMWR Morb Mortal Wkly Rep.* 2019;68(31):679-686.
 - Compton WM, **Jones CM**. Epidemiology of the U.S. opioid crisis: the importance of the vector. *Ann NY Acad Sci.* 2019;doi:10.1111/nyas.14209.
 - Compton WM, Han B, **Jones CM**. Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. *Drug Alcohol Depend.* 2019;204:107468.
 - Compton WM, **Jones CM**, Baldwin GT, Harding FM, Blanco C, Wargo EM. Targeting youth to prevent later substance use disorder: an underutilized response to the U.S. opioid crisis. *Am J Public Health.* 2019;109(S3):S185-S189.
 - **Jones CM**. Syringe services programs: an examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. *Int J Drug Policy.* 2019;70:22-32.
 - **Jones CM**, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend.* 2019;197:78-82.
 - **Jones CM**, McCance-Katz EF. Relationship between recency and frequency of youth cannabis use on other substance use. *J Adolesc Health.* 2019;64(3):411-413.
 - **Jones CM**, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waived to prescribe buprenorphine for the treatment of opioid use disorder. *Addiction.* 2019;114(3):471-482.
 - Han B, Compton W, Blanco C, **Jones CM**. Time since first cannabis use and 12-month prevalence of cannabis use disorder among youth and emerging adults in the United States. *Addiction.* 2019;114(4):698-707.

- Compton W, Han B, Blanco C, **Jones CM**. Misuse of immediate-release stimulants: response to Diller. *Am J Psychiatry*. 2019;176(1):77-78.

2018

- Saloner B, Levin J, Chang HY, **Jones C**, Alexander GC. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion. *JAMA Netw Open*. 2018;1(4):e181588.
- Heyward J, **Jones CM**, Compton WM, et al. Coverage of nonpharmacologic treatments for low back pain among U.S. public and private insurers. *JAMA Network Open*. 2018;1(6):e183044.
- **Jones CM**, Compton WM, Einstein E. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. *JAMA*. May 1;319(17):1819-1821.
- Han B, Compton W, Blanco C, **Jones CM**. Correlates of prescription opioid use, misuse, use disorders, and motivations for misuse among U.S. adults. *J Clin Psychiatry*. 2018;79(5). *J Clin Psychiatry*.
- Murimi IB, Chang HY, Bicket M, **Jones CM**, Alexander GC. Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users. *Pharmacol Epidemiol Drug Saf*. 2018. Accepted.
- Blanco C, Han B, **Jones CM**, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. *J Clin Psychiatry*. 2018;79(6).
- Johnson K, **Jones C**, Compton W, Baldwin G, Fan J, Mermin J, Bennet J. Federal response to the opioid crisis. *Curr HIV/AIDS Rep*. 2018;15(4):293-301.
- Lin DH, **Jones CM**, Compton WM, Heyward et al. Prescription drug coverage for treatment of low back pain among US Medicaid, Medicare Advantage, and Commercial Insurers. *JAMA Network Open*. 2018;1(2):e180235.
- Compton WM, Han B, Blanco C, Johnson K, **Jones CM**. Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. *Am J Psychiatry*. 2018. Apr 16:appiajp201817091048.
- Han B, Compton WM, Blanco C, **Jones CM**. Trends in and correlates of medical marijuana use among adults in the United States. *Drug Alcohol Depend*. 2018 May 1;186:120-129.
- Han B, Compton WM, Blanco C, **Jones CM**. Prescription opioid use, misuse, and use disorders in U.S. adults. *Ann Intern Med*. 2018;168(5):383-384.
- Zivin K, White JO, Chao S, Christensen AL, Horner L, Petersen DM, Hobbs MR, Capreol G, Halbritter KA, **Jones CM**. Implementing electronic health record default settings to reduce opioid overprescribing: A pilot study. *Pain Med*. 2018 Jan 9. doi: 10.1093/pm/pnx304.
- Chang HY, Murimi IB, **Jones CM**, Alexander GC. Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers. *Addiction*. 2018;113(4):677-686.
- Heins SE, Sorbero MJ, **Jones CM**, Dick AW, Stein BD. High-risk prescribing to Medicaid enrollees receiving opioid analgesics: individual and county-level factors. *Subst Use Misuse*. 2018;Jan5:1-11.

2017

- Compton WM, **Jones CM**, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. *Res Social Adm Pharm*. 2017. Dec 31. Pii:S1551-7411(17)30977-4.
- **Jones CM**. Trends and Key Correlates of Prescription Opioid Injection Misuse in the United States Addictive Behaviors. *Addictive Behaviors*. 2017 Nov 22;78:145-152.
- Mack KA, **Jones CM**, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas- United States. *Am J Transplant*. 2017;17(12):3241-3252.
- Thomas CP, Doyle E, Kriener PW, **Jones CM**, Dubenitz J, Horan A, Stein BD. Prescribing patterns of buprenorphine waived physicians. *Drug Alcohol Depend*. 2017;181:213-218.

- Mack KA, **Jones CM**, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas – United States. *MMWR Surveill Summ.* 2017;66(19):1-12.
- Han B, **Jones CM**, Blanco C, Compton WM. National trends in and correlates of nonmedical use of prescription stimulants, nonmedical use frequency, and use disorders. *J Clin Psychiatry.* 2017;.pii17m11760.
- Han B, Compton WM, Blanco C, Crane E, Lee J, **Jones CM**. Prescription opioid use, misuse, and use disorders in U.S. adults; 2015 National Survey on Drug Use and Health. *Ann Intern Med.* 2017. Aug 1. Doi: 10.7326/M17-0865.
- Han B, Compton WM, **Jones CM**, Blanco C. Cannabis use and cannabis use disorders among youth in the United States, 2002-2014. *J Clin Psychiatry.* 2017 Jul 5. Pii:16m10948.
- **Jones CM**, Christensen A, Gladden RM. Increases in prescription opioid injection among treatment admissions in the United States, 2004-2013. *Drug Alcohol Depend.* 2017 Jul 1:176:89-95.
- Mack KA, **Jones CM**, McClure RJ. Physician Dispensing of Oxycodone and Other Commonly Used Opioids, 2000-2015, United States. *Pain Med.* 2017 Mar 15. doi: 10.1093/pm/pnx007.
- **Jones CM**, Baldwin GT, Compton WM. Recent increases in cocaine-related overdose deaths and the role of opioids. *Am J Public Health.* 2017;107(3):430-432.
- **Jones CM**. The paradox of decreasing nonmedical opioid analgesic use and increasing abuse or dependence – An assessment of demographic and substance use trends, United States, 2003-2014. *Addict Behav.* 2017;65:229-235.
- Compton WM, Han B, Hughes A, **Jones CM**, Blanco C. Use of marijuana for medical purposes among adults in the United States. *JAMA* 2016; Jan 10;317(2):209-211.

2016

- **Jones CM**, Baldwin GT, Tefera L. State regulations and opioid use among disabled adults. *N Engl J Med.* 2016.375(14):1396-1397.
- Van Handell MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, **Jones CM**, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. *J Acquir Immune Defic Syndr.* 2016;73(3):323-331.
- **Jones CM**, Muhuri PK, Lurie PG. Trends in the Nonmedical Use of OxyContin, United States, 2006-2013. *Clin J Pain.* 2016. Aug 10.
- Easterling KW, Mack KA, **Jones CM**. Location of fatal prescription opioid-related deaths in 12 states, 2008-2010. Implications for prevention programs. *J Safety Res.* 2016;58:105-9.
- Compton WM, Han B, **Jones CM**, Blanco C, Hughes A. Marijuana Use and Use Disorders among Adults in the United States, 2002-2014; an analysis of annual cross-sectional surveys. *Lancet Psychiatry.* 2016. 3(10):954-964.
- El Burai Felix S, Mack KA, **Jones CM**. Trends in the distribution of opioids in Puerto Rico, 1999-2013. *PR Health Sci J.* 2016;35(3):165-9.
- Kattan JA, Tuazon E, Paone D, Dowell D, Vo L, Starrels JL, **Jones CM**, Kunins HV. Public health detailing – A successful strategy to promote judicious opioid analgesic prescribing. *Am J Public Health.* 2016;106(8):1430-8.
- **Jones CM**, Baldwin GT, Manocchio T, White JO, Mack KA. Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths, United States, 2002-2014. *Morb Mortal Wkly Rep.* 2016;65(26):667-71.
- **Jones CM**, Lurie PG, Compton WM. Increase in naloxone prescriptions dispensed in U.S. retail pharmacies since 2013. *Am J Public Health.* 2016;106(4):689-90.

- Hwang CS, Kang EM, Kornegay CJ, Staff JA, **Jones CM**, McAninch JK. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014. *Am J Prev Med.* 2016 Apr 11. Pii:S0749-3797(16)00094-5.
- Compton WM, **Jones CM**, Baldwin GT. Nonmedical prescription-opioid use and heroin use. *N Engl J Med.* 2016;374(13):1296
- Paulozzi LJ, Zhou C, **Jones CM**, Xu L, Florence CS. Changes in the medical management of patients on opioid analgesics following a diagnosis on substance abuse. *Pharmacoepidemiol Drug Saf.* 2016Feb 10. doi: 10.1002/pds.3980.
- **Jones CM**, Lurie PG, Throckmorton DC. Effect of US drug enforcement administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. *JAMA Internal Med.* 2016 Jan 25. doi: 10.1001/jamainternmed.2015.7799
- Compton WM, **Jones CM**, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. *N Engl J Med.* 2016;14:374:154-63.

2015

- Han B, Compton WM, **Jones CM**, Cai R. Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. *JAMA* 2015;314(14):1468-78.
- **Jones CM**, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and Substance Use Trends Among Heroin Users – United States, 2002-2013. *MMWR Morb Mortal Wkly Rep.* 2015;64(26):719-25.
- **Jones CM**, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication Assisted Treatment. *Am J Public Health* 2015 Aug;105(8):e55-63
- **Jones CM**, Mcanich JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. *Am J Prev Med.* 2015;49(4):493-501.
- Levy B, Paulozzi L, Mack K, **Jones CM**. Trends in Opioid Analgesic Prescribing Rates by Specialty, United States, 2007-2012. *Am J Prev Med.* 2015 Apr 17. pii: S0749-3797(15)00089-6.
- Franklin G, Sabel J, **Jones CM**, et al. A Comprehensive Approach to Address the Prescription Opioid Epidemic in Washington State - Milestones and Lessons Learned. *Am Journal Public Health* 2015 Mar;105(3):463-9.
- Mack KA, Zhang K, Paulozzi LJ, **Jones CM**. Opioid Analgesic Prescriptions among Americans with Medicaid, 2010. *JHCPU.* 2014. *J Health Care Poor Underserved.* 2015;26(1):182-98.
- Yang Z, Wilsey B, Bohm M, et al. Defining Risk for Prescription Opioid Overdose: Pharmacy Shopping and Overlapping Prescriptions among Long-Term Opioid Users in Medicaid. *J Pain.* 2015 Feb 10 pii: S1526-5900(15)00530-1.

2014

- **Jones CM**, Paulozzi LJ, Mack KA. Alcohol involvement in opioid analgesic and benzodiazepine abuse-related emergency department visits and drug-related deaths, United States, 2010. *MMWR. Morbidity and mortality weekly report.* 10/2014; 63(40):881-885.
- **Jones CM**, Lurie P, Woodcock J. Addressing prescription opioid overdose – data support a comprehensive policy approach. 2014. *JAMA.* 2014 Nov 5;312(17):1733-4
- Haegerich T, Paulozzi LJ, Manns B, **Jones CM**. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. *Drug and alcohol dependence* 12/2014; 145C:34-47. DOI: 10.1016/j.drugalcdep.2014.10.001.
- Mack KA, **Jones CM**. Prescription Analgesic Dispensing by Gender – United States, 2009-2014. *SAVIR Abstract.* 2014.

- Strickler G, Kriener P, Panas L., et al. Development and design of the Prescription Behavior Surveillance System (PBSS) preliminary results. 142nd APHA Annual Meeting and Exposition 2014; 11/2014
- Paulozzi LJ, Zhang K, **Jones CM**, Mack, KA. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. *J Am Board Fam Med.* 2014 May-Jun;27(3):329-38.
- Kattan J, Paone D, Dowell D., et al. Public health detailing as a successful strategy to change healthcare provider knowledge about opioid analgesic prescribing practices. 2014 Council of State and Territorial Epidemiologists Annual Conference; 06/2014
- Vo-Green L, Paone D, Kunins H. Public health detailing : a promising , innovative strategy to change opioid analgesic prescribing. 65th Society for Public Health Education Annual Conference, Baltimore, MD; 03/2014
- Faul M, Sugerman DE, Sasser SM, Levy BA, Paulozzi LJ, **Jones CM**. Factors that affect naloxone administration by emergency medical services providers following a drug overdose. *SAEM Abstracts* 2014;S32.

2013

- **Jones CM**, Paulozzi LJ, Mack KA. Source of prescription opioid pain relievers by frequency of past year nonmedical use, United States, 2008-2011. *JAMA Intern Med.*2014
doi:10.1001/jamainternmed.2013.12809.
- Paulozzi LJ, Warner M, **Jones CM**. Defining controlled substances overdose: some challenges. *J Clin Toxicol* 2013;3:175. doi: 10.4172/2161-0495.1000175.
- Department of Health and Human Services. Addressing prescription drug abuse in the United States – current activities and future opportunities. 2013
- Department of Health and Human Services. Prescription drug monitoring program interoperability standards – A Report to Congress. 2013.
- Mack KA, **Jones CM**, Paulozzi LJ, Zhang K. Gender differences in opioid prescriptions among Americans with Medicaid. 141st APHA Annual Meeting and Exposition 2013; 11/2013
- Centers for Disease Control and Prevention. Patient review and restriction programs: lessons learned from state Medicaid programs. CDC Expert Panel meeting report. 2013.
- Berlin D, Farmer BM, Rao RB, Rella J, Kunins H, Dowell D, Graber N, Hoffman RS, Karpati A, Weiss D, **Jones CM**, Toprani A, Ridpath A. Deaths and sever adverse events associated with anesthesia-assisted rapid opioid detoxification – new york city, 2012. *MMWR* 2013;62(38):777-780.
- Smith S, Dart R, Katz N, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTION systematic review and recommendations. *Pain.* 2013 pii: S0304-3959(13)00329-1. doi: 10.1016/j.pain.2013.05.053.
- Ying L, Logan J, Zhang K, **Jones CM**, Paulozzi L. Potential Misuse and Inappropriate Prescription Practices involving Opioid Analgesics among Commercially Insured Americans. *AJMC* 2013. *Am J Manag Care.* 2013;19(8):648-65.
- Mack KA, **Jones CM**, Paulozzi LJ. Vital Signs: Overdoses of Prescription Opioid Pain Relievers and Other Drugs Among Women - United States, 1999-2010. *MMWR Morb Mortal Wkly Rep.* 2013 Jul 5;62(26):537-542.
- Logan J, Ying L, Paulozzi L, Zhang K, **Jones CM**. Opioid prescribing in emergency departments: the prevalence of potentially inappropriate prescribing and misuse. *Med Care* 2013 Aug;51(8):646-53.
- **Jones CM**, Mack KA, Paulozzi LJ. Pharmaceutical Overdose Deaths, United States, 2010. *JAMA.* 2013 Feb 20;309(7):657-9.

- **Jones CM.** Heroin Use and Heroin Use Risk Behaviors Among Nonmedical Users of Opioid Pain Relievers, United States, 2002-2003 and 2008-2010. *Drug Alcohol Depend.* 2013 doi:pii: S0376-8716(13)00019-7. 10.1016/j.drugalcdep.2013.01.007.
- Modari F, Mack K, Hick P, Benoit S, Park S, **Jones C**, Proescholdbell S, Paulozzi L. Relationship of Opioid Prescription Sales and Overdoses, North Carolina. *Drug Alcohol Depend.* 2013 doi:pii: S0376-8716(13)00018-5. 10.1016/j.drugalcdep.2013.01.006.

2012

- Paulozzi LJ, Mack KM, **Jones CM.** Vital Signs: Risk for Overdose from Methadone Used for Pain Relief – United States, 1999-2010. *MMWR*, Jul 6;61:493-7. 2012.
- **Jones CM.** Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. *Arch Intern Med.* Jun 25:1-2. doi: 10.1001/archinternmed.2012.2533. 2012
- Popovich T, Paulozzi LJ, Baldwin G, **Jones CM**, Franklin G, Kerlikowske RG. CDC Grand Rounds: Prescription Drug Overdoses – A U.S. Epidemic. *CDC MMWR.* Vol 61, 10-13. 2012.

2011

- Paulozzi LJ, **Jones CM**, Mack KM, Rudd RA. Vital Signs: Overdoses of Prescription Opioid Pain Relievers – United States, 1999-2008. *CDC MMWR.* Vol 60, 1487–92. 2011.
- Office of National Drug Control Policy. National Drug Control Strategy 2011. Office of National Drug Control Policy, The White House. Washington, DC. 2011.
- Office of National Drug Control Policy. Epidemic: Responding to America’s Prescription Drug Abuse Crisis. Office of National Drug Control Policy, The White House. Washington, DC. 2011.
- Kerlikowske RG, **Jones CM**, LaBelle R, Condon TP. Prescription Drug Monitoring Programs – Lack of Effectiveness or Call To Action? *J Pain Med.* 12(5):687-689. 2011.

2008

- **Jones CM.** Pleiotropic Effects of Statins: A Panacea? *US Pharm.* 33(10):56-61. 2008.
- **Jones CM**, Earnhardt PI, Szcotka AD. Two Phased Physician and Patient Education Program to Improve Awareness of Controlled Substance Utilization in an Employer Group. *J Manag Care Pharm.* Abstract. 14:2:249. 2008.
- **Jones CM.** Thalidomide: New Cancer Uses for an Old Drug. *US Pharm.* 33(7)(Oncology suppl):3-13. 2008.
- **Jones CM**, Harshbarger J. Pediatric/Adolescent Vaccine Update. *US Pharm.* 33(3):28-47. 2008.
- **Jones CM**, Earnhardt PI. Targeted Therapy for Non-Small Cell Lung Cancer: An Update. *US Pharm.* 32(10):5-13. 2008.
- **Jones CM.** Acute Coronary Syndrome: A Primer for Pharmacists. *U.S. Pharm.* 32:2:52-57. 2008.

2007

- **Jones CM.** Sarcoidosis. *U.S. Pharm.* 32(7):HS-18-HS-25. 2007.

2006

- Kazzi ZN, **Jones CM**, Morgan BW. Seizures in a Pediatric Patient with a Tiagabine Overdose. *J Med Toxicology.* 2:4: 160-162. 2006.
- **Jones CM**, Nykamp DN. Vitamin E for the Prevention of Cardiovascular Disease? What Pharmacists Need to Know. *U.S. Pharm.* 31:10: 37-44. 2006.

2005

- Kazzi ZN, **Jones CM**, Craegin LS, Morgan B.W. Retrospective Review of Exposures to Tiagabine as Reported to a Regional Poison Center. *J Toxicol Clin Toxicol* Abstract 43(6):728. 2005.

2004

- Kazzi ZN, **Jones CM**, Hamilton E, Morgan BW Tiagabine Overdose in a Toddler Resulting in Seizure Activity. *J Toxicol Clin Toxicol* Abstract 42:721. 2004.

Awards and Honors:

- PHS Unit Commendation 2022
- PHS COVID-19 Campaign Medal 2021(EA)
- Presidential Unit Citation, PHS 2021
- PHS Unit Commendation 2021
- PHS COVID-19 Campaign Medal 2020
- PHS Unit Commendation 2020
- PHS Outstanding Unit Citation, HHS 2020
- PHS Outstanding Unit Citation, HHS 2019
- PHS Special Assignment Award, HHS 2019
- Secretary’s Distinguished Service Award, HHS 2018
- Secretary’s Meritorious Service Award, HHS 2018
- PHS Commissioned Corps, Exceptional Proficiency Promotion to O-6, Office of the Secretary 2017
- Secretary’s Distinguished Service Award, HHS 2016
- Secretary’s Distinguished Service Award, HHS 2015
- Presidential Unit Citation, PHS 2015
- Office of the Secretary Insignia Badge 2015
- Commendation Medal (PHS), Centers for Disease Control and Prevention (CDC) 2015
- Commendation Medal (PHS), Office of the Assistant Secretary for Health 2015
- CDC/NCIPC Directors Award 2014
- PHS Commissioned Corps, Exceptional Proficiency Promotion to O-5, CDC 2013
- CDC/NCIPC Excellence in Front Line Public Health Science Award 2013
- Unit Commendation (PHS), Office of the Surgeon General 2013
- Young Alumni Award, Mercer University School of Pharmacy 2012
- Achievement Medal (PHS), Centers for Disease Control and Prevention 2012
- Outstanding Service Medal (PHS), White House Office of National Drug Control Policy 2011
- Outstanding Unit Citation (PHS), Food and Drug Administration 2011
- Achievement Medal (PHS), Office of the Surgeon General 2011
- Unit Commendation (PHS), Food and Drug Administration 2011
- Unit Commendation (PHS), Food and Drug Administration 2011
- Special Assignment Award (PHS), Office of the Surgeon General 2011
- Dr. Frances Kelsey Drug Safety Excellence Award, Food and Drug Administration 2011
- Achievement Medal (PHS), Food and Drug Administration 2010
- PHS Citation (PHS), Assistant Secretary for Preparedness and Response 2010
- FDA Commissioner’s Special Citation – H1N1 Flu response, Food and Drug Administration 2010
- Response Service Award (PHS), Office of the Surgeon General 2010
- JOAG Chair’s Award 2010
- PharmPAC Letter of Appreciation 2010
- Commendation Medal (PHS), Food and Drug Administration 2009

- Achievement Medal (PHS), Food and Drug Administration 2009
- Field Medical Readiness Badge (PHS) 2009
- Commissioned Corps Training Ribbon 2009
- PharmPAC Certificate of Appreciation 2009
- JOAG Letter of Appreciation 2009
- JOAG Chair's Award 2009
- CDC Silo Busters: Collaborative Success Award, Pandemic Influenza Task Force 2007
- CDC/COTPER Directors Recognition Award 2007
- R.C Hood Award - Mercer University, Valedictorian for PharmD program 2006
- GlaxoSmithKline Patient Care Award - Mercer University 2006
- Phi Kappa Phi Academic Society 2005
- Oliver M. Littlejohn Award-Mercer University 2005
- Rho Chi Pharmaceutical Honor Society 2004
- Minnie Meyer Award - Mercer University 2004
- M. A. Chambers Award – Mercer University 2003

Professional Memberships and Activities:

- American Pharmacists Association 2016-Present
- Journal Reviewer JAMA 2014-Present
- Journal Reviewer American Journal of Public Health 2014-Present
- Journal Reviewer Drug and Alcohol Dependence 2014-Present
- Journal Reviewer American Journal of Preventive Medicine 2014-Present
- Mercer University College of Pharmacy and Health Sciences Board of Visitors 2012-2015
- Commissioned Officers Association 2009-2015
- American Public Health Association 2013-Present
- Adjunct Instructor, University of Maryland East. Shore School of Pharmacy 2011-2012
- Adjunct Instructor, Mercer University School of Pharmacy 2007-2010
- Adjunct Instructor, Univ. California San Diego School of Pharmacy 2009-2010
- American Association of Poison Control Centers 2003-2013
- American Society of Health Systems Pharmacists 2003-2006

License:

Georgia Registered Pharmacist License: RPH023229 2006-Present

Certifications and Special Skills:

- American Pharmacists Association Pharmacy Vaccine Program 2010-2017
- American Association of Poison Control Centers, Certified Poison Specialist 2008-2015
- Basic Life Support 2015-Present